Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is conducting a clinical study titled A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate. The study aims to evaluate the side effects of the LY3971297 injection, administered under the skin, and its pharmacokinetics in various participant groups. This research is significant as it explores potential treatments for obesity and hypertension.
Intervention/Treatment: The study tests the drug LY3971297, administered subcutaneously and intravenously. It is designed to assess the drug’s safety, dosage, and how it is processed by the body.
Study Design: This Phase 1 interventional study uses a randomized, parallel assignment model with double masking for participants and investigators. Its primary purpose is basic science, aiming to gather foundational data on LY3971297.
Study Timeline: The study began on December 7, 2023, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and progress.
Market Implications: As Eli Lilly advances this study, investor interest may rise due to the potential market for new obesity and hypertension treatments. Successful outcomes could positively impact Eli Lilly’s stock performance, especially if LY3971297 proves effective. Competitors in the pharmaceutical industry may also respond to these developments, potentially influencing market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.